(Created page with "{{ColumbiaNYC_navbar}} <html> <body id="page-top"> <!-- Full Width Jumbotron Header --> <div class="jumbotron"> <div class="container"> <h1>Brainstorming</h1>...") |
|||
Line 15: | Line 15: | ||
<!-- Page Content --> | <!-- Page Content --> | ||
<div class="container"> | <div class="container"> | ||
+ | <h2>T-cell Targeted Nociceptive Sodium Channels</h2> | ||
+ | <p>Nav1.7 is a voltage-gated sodium channel expressed on nociceptive neurons, neurons responsible for transmitting pain signals from the PNS to the CNS. | ||
+ | Nav1.7 is essential for normal pain sensation; if it is not expressed, the patient will not feel pain at all, and if it is overexpressed, the patient will experience chronic pain (20% of the population worldwide). | ||
+ | Nav1.7 is therefore a prime therapeutic target whose blockage by an T-cell antibody would mitigate pain, with the T cell acting as a potential analgesic. | ||
+ | A circuit would be designed so that once the T cell binds to the epitope, a chimeric antigen receptor (CAR) could be engineered to be drug-switchable so that the T cells are controllable, which is not currently the case. | ||
+ | This way, a physician could titrate cell activity and control timing with a drug, which is potentially safer. </p> | ||
</div> | </div> |
Revision as of 15:04, 7 July 2017
Brainstorming
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Sint, explicabo dolores ipsam aliquam inventore corrupti.
T-cell Targeted Nociceptive Sodium Channels
Nav1.7 is a voltage-gated sodium channel expressed on nociceptive neurons, neurons responsible for transmitting pain signals from the PNS to the CNS. Nav1.7 is essential for normal pain sensation; if it is not expressed, the patient will not feel pain at all, and if it is overexpressed, the patient will experience chronic pain (20% of the population worldwide). Nav1.7 is therefore a prime therapeutic target whose blockage by an T-cell antibody would mitigate pain, with the T cell acting as a potential analgesic. A circuit would be designed so that once the T cell binds to the epitope, a chimeric antigen receptor (CAR) could be engineered to be drug-switchable so that the T cells are controllable, which is not currently the case. This way, a physician could titrate cell activity and control timing with a drug, which is potentially safer.